Nanotoxicology expert David W. Hobson suggests that industry must step up to gather and assess data on the safety of nanomaterials before government alone shapes a new regulatory model.

Read about it in tomorrow's edition of MDD Perspectives, an op-ed e-zine that provides fresh commentary and opinions on issues that you can't find anywhere else. And best of all, it's free. If you don't already subscribe to this complimentary e-zine, go to medicaldevicedaily.com to sign up.